DAWN logo
DAWN
Day One Biopharmaceuticals

Pediatric Oncology Adoption And Pipeline Expansion Will Drive Future Success

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
29 Apr 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$26.25
74.3% undervalued intrinsic discount
24 Jul
US$6.74
Loading
1Y
-49.2%
7D
-5.1%

Author's Valuation

US$26.3

74.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value